SBIR TOPIC 256 - INNOVATIVE METHODS FOR MANUFACTURING SAFE, EFECTIVE CANCER THER

Information

  • Research Project
  • 7962834
  • ApplicationId
    7962834
  • Core Project Number
    261200900031C-0-0-1
  • Full Project Number
    261200900031C-0-0-1
  • Serial Number
    0
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/2009 - 16 years ago
  • Project End Date
    6/14/2010 - 15 years ago
  • Program Officer Name
  • Budget Start Date
    -
  • Budget End Date
    -
  • Fiscal Year
    2009
  • Support Year
  • Suffix
  • Award Notice Date
    -
Organizations

SBIR TOPIC 256 - INNOVATIVE METHODS FOR MANUFACTURING SAFE, EFECTIVE CANCER THER

The ultimate goal of this project is to develop an improved system for recombinant antibody manufacturing in mammalian cells through the controlled in vivo co-expression of non-native transcription activators and positive cofactors that function to specifically amplify recombinant gene expression. Such a system is not currently commercially available and will allow researchers and drug development companies to produce recombinant antibodies and other recombinant protein molecules at a significantly higher yield and lower cost than currently available systems.. We propose to develop a series of novel chromosomally-integratable mammalian expression vectors that direct recombinant protein expression via a strong viral promoter and are activated by the co-expression of the well characterized chimeric transcription factor GAL4-VP16 and positive cofactor PC4 .. We are confident that we can achieve this goal and develop this technology as our company, AscentGene, Inc, has the ability to produce stable cell lines, characterize protein expression levels, and purify recombinant proteins .. In addition, our team has over 17 years of experience including 25+ peer-reviewed publications in the transcription factor field, and over 30 years of combined experience in recombinant protein expression and purification in mammal[an systerns.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    N43
  • Administering IC
    CA
  • Application Type
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    219821
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:219821\
  • Funding Mechanism
    Contracts, Extramural
  • Study Section
  • Study Section Name
  • Organization Name
    ASCENTGENE, INC.
  • Organization Department
  • Organization DUNS
    021529830
  • Organization City
    ROCKVILLE
  • Organization State
    MD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    20850
  • Organization District
    UNITED STATES